Cutaneously applied acyclovir acts systemically in the treatment of herpetic infection in the hairless mouse

Antiviral Research

Volumn 35, Issue 3, 1997, Pages 157-165

  Bolger, G T ^a   Allen, T ^a   Garneau, M ^a   Lapeyre, N ^a   Liard, F ^a   Jaramillo, J ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Acylovir; Cutaneous; Hairless mouse; Herpes; Topical

Indexed keywords

ACICLOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HERPES; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

ACYCLOVIR; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; MICE; MICE, INBRED HRS; SKIN ABSORPTION; SKIN DISEASES, INFECTIOUS;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2;

EID: 0030853939     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)00024-7     Document Type: Article

References (24)

1. Bond, J.R., Barry, B.W., 1988. Limitations of HM skin as a model for in vitro permeation studies through human skin: Hydration damage. J. Invest. Dermatol. 90, 486-489.
2. Collins, P., 1983. The spectrum of antiviral activities of acyclovir in vitro and in vivo. J. Antimicrob. Chemother. 12 (B), 19-27.
3. Cooper, E.R., Merritt, E.W., Smith, R.L., 1985. Effect of fatty acids and alcohols on the penetration of acyclovir across skin in vitro. J. Pharm. Sci. 74, 688-689.
4. Dalvi, U.G., Zatz, J.L., 1981. Effect of nonionic surfactants on penetration of dissolved benzocaine through HM skin. J. Soc. Cosmet. Chem. 32, 87-94.
5. de Clercq, E., 1984. Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovynil)-2′-deoxyuridine and related compounds. Antimicrob. Agents Chemother. 26, 155-159.
6. de Miranda, P., Krasny, H.C., Page, D.A., Elion, G.B., 1991. The disposition of acyclovir in different species. J. Pharmacol. Exp. Ther. 219, 309-315.
7. de Miranda, P., Good, S.S., 1992. Species differences in the metabolism and disposition of antiviral nucleoside analogues: 1. Acyclovir. Antiviral Chem. Chemother. 3, 1-8.
8. Durrheim, H., Flynn, G.L., Higuchi, W.I., Behl, C.R., 1980. Permeation of hairless mouse skin I: Experimental methods and comparison with human epidermal permeation by alkaloids. J. Pharm. Sci. 69, 781-786.
9. Freeman, D.J., Spruance, S.L., 1986a. Efficacy of topical treatment for herpes simplex virus infections: Predictions from an index of drug characteristics in vitro. J. Infect. Diseases 153, 64-70.
10. Freeman, D.J., Spruance, S.L., 1986b. Efficacy of topical treatment for herpes simplex virus infections: Predictions from an index of drug characteristics in vitro. J. Infect. Diseases 153, 6470.
11. Freeman, D.J., Sheth, N.V., Spruance, S.L., 1986. Failure of topical acyclovir in ointment to penetrate human skin. Antimicrob. Agents. Chemother. 29, 730-732.
12. Ghanem, A.-H., Mahmoud, H., Higuchi, W.I., Liu, P., Good, W.R., 1992. The effects of ethanol on the transport of lipophilic and polar permeants across HM skin: Methods/ validation of a novel approach. Int. J. Pharm. 78, 157-166.
13. Kern, E.R., 1982. Acyclovir treatment of experimental genital herpes simplex virus infections. Am. J. Med. 73, 100-108.
14. Kern, E.R., Richards, J.T., Overall, J.C., Glasgow, L.A., 1983. Acyclovir treatment of experimental genital herpes simplex virus infections. I. Topical therapy of type 2 and type 1 infections of mice. Antiviral Res. 3, 253-267.
15. Kern, E.R., Richards, J.T., Overall, J.C., 1986. Acyclovir treatment of disseminated herpes simplex virus type 2 infection in weanling mice: Alteration of mortality and pathogenesis. Antiviral Res. 6, 189-195.
16. Klein, R.J., 1982. Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds. Am. J. Med. 73, 138-142.
17. Lee, P.H., Su, M.-H., Kern, E.R., Higuchi, W.I., 1992a. Novel animal model for evaluating topical efficacy of antiviral agents: Flux vs efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice. Pharm. Res. 9, 979-989.
18. Lee, P.H., Su, M.-H., Kern, E.R., Higuchi, W.I., 1992b. Novel animal model for evaluating topical efficacy of antiviral agents: Flux vs efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice. Pharm. Res. 9, 979-989.
19. Lee, P.H., Su, M.-H., Ghanem, A.-H., Inamori, T., Kern, E.R., Higuchi, W.I., 1993. An application of the C* concept in predicting the topical efficacy of finite dose acyclovir in the treatment of cutaneous HSV-1 infections in hairless mice. Int. J. Pharm. 93, 139-152.
20. Mascher, H., Kikuta, C., 1992. New, high-sensitivity high-performance liquid chromatographic method for the determination of acyclovir in human plasma, using fluorometric detection. J. Chrom. Biomed. Appl. 583, 122-127.
21. Šalamoun, J., Šprta, V., Sládek, T., Smrz, M., 1987. Determination of acyclovir in plasma by column liquid chormatography with fluorescence detection. J. Chrom. Biomed. Appl. 420, 197-202.
22. Shannon, W.M., Westbrook, L., Higuchi, W.I., Sugibayashi, K., Baker, D.C., Kumar, S.D., Fox, J.L., Flynn, G.L., Ho, N.F.H., Vaidyanathan, R., 1985. Influence of 1-dodecylazacycloheptan-2-one (Azone) on the topical therapy of cutaneous herpes simplex virus type-1 infection in hairless mice with 2′,3′-di-o-acetyl-9-β-D arabinofuranosyladenine and 5′-o-valeryl-9-β-D-arabinofuranosyladenine. J. Pharm. Sci. 74, 1157-1161.
23. Spruance, S.L., McKeough, M.B., Cardinal, J.R., 1984. Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection. Antimicrob. Agents Chem. 25, 10-15.
24. Spruance, S.L., Freeman, D.J., 1990. Topical treatment of cutaneous herpes simplex virus infections. Antiviral Res. 14, 305-321.